{"id":"precision-dosing-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including tuberculosis, fungal, and opportunistic)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Autoimmune phenomena (lupus-like syndrome)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane TNF-alpha, preventing its interaction with TNF receptors on immune cells. This blocks the inflammatory cascade driven by TNF-alpha, reducing production of pro-inflammatory cytokines and adhesion molecules. PRECISION dosing refers to therapeutic drug monitoring and individualized dosing optimization to maintain therapeutic drug levels while minimizing toxicity.","oneSentence":"Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:27.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT04974099","phase":"PHASE2, PHASE3","title":"Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-10-01","conditions":"Crohn Disease","enrollment":6},{"nctId":"NCT05660746","phase":"PHASE2, PHASE3","title":"Precise Infliximab Exposure and Pharmacodynamic Control","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07-01","conditions":"Crohn Disease","enrollment":180},{"nctId":"NCT04982172","phase":"PHASE4","title":"Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases","enrollment":80},{"nctId":"NCT04131504","phase":"","title":"Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-10-16","conditions":"Crohn's Disease, IBD","enrollment":239},{"nctId":"NCT02624037","phase":"NA","title":"Precision IFX: Using a Dashboard to Individualize Infliximab Dosage","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-01","conditions":"Inflammatory Bowel Disease","enrollment":189},{"nctId":"NCT02453776","phase":"PHASE4","title":"Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-05","conditions":"Inflammatory Bowel Disease","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PRECISION dosing Infliximab","genericName":"PRECISION dosing Infliximab","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}